Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates

Cara Therapeutics (CARA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.51%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.53 per share when it actually produced a loss of $0.52, delivering a surprise of 1.89%.Over the last four quarters, the compa ...